1
|
Low S, Wu H, Jerath K, Tibolla A, Fogal B, Conrad R, MacDougall M, Kerr S, Berger V, Dave R, Villalona J, Pantages L, Ahlberg J, Li H, Van Hoorick D, Ververken C, Broadwater J, Waterman A, Singh S, Kroe-Barrett R. VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis. MAbs 2021; 12:1709322. [PMID: 31924119 PMCID: PMC6973309 DOI: 10.1080/19420862.2019.1709322] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identification of BI 655088, a potent biotherapeutic antagonist to CX3CR1. BI 655088 is a potent CX3CR1 antagonist that, upon therapeutic dosing, significantly inhibits plaque progression in the standard mouse model of atherosclerosis. BI 655088 represents a novel and highly selective biotherapeutic that could reduce inflammation in the atherosclerotic plaque when added to standard of care treatment including statins, which could result in a significant decrease in atherothrombotic events in patients with existing cardiovascular disease.
Collapse
Affiliation(s)
- Sarah Low
- Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Haixia Wu
- Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Kavita Jerath
- Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Annette Tibolla
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Birgit Fogal
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Rebecca Conrad
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Margit MacDougall
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Steven Kerr
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Valentina Berger
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Rajvee Dave
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Jorge Villalona
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Lynn Pantages
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Jennifer Ahlberg
- Biotherapeutics Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Hua Li
- Biotherapeutics Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | | | - Cedric Ververken
- Project Management, Ablynx a Sanofi Company, Zwijnaarde, Belgium
| | - John Broadwater
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Alisa Waterman
- Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Sanjaya Singh
- Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| | - Rachel Kroe-Barrett
- Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
| |
Collapse
|
2
|
Ingraham RH, Bananis E, Hansen G, Proudfoot JR, Latli B, Tibolla A, Akiba I, Ueda S, Kameda K, Barsoumian EL, Jakes S, Papov V. Molecular targets of immunosuppressive pyrazole derivatives: From TRPC channels to mTOR. FASEB J 2008. [DOI: 10.1096/fasebj.22.1_supplement.721.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Edward L. Barsoumian
- retiredNippon Boehringer Ingelheim Kawanishi Pharma Research InstituteKawanishiJapan
| | | | - Vladimir Papov
- Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Inc.RidgefieldCT
| |
Collapse
|